Citius Pharmaceuticals (NASDAQ: CTXR) CEO: Myron Holubiak About: Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market position or market exclusivity. By using previously approved drugs with substantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development. Citius is currently advancing two proprietary product candidates, our Mino-Lok™ product and a Hydrocortisone-Lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care. WSA caught up with Citius CEO Myron Holubiak to provide an update since their previous conversation from January 2018. Mr Holubiak provided an update on CTXR's Mino-Lok platform, discussed their partnership with MD Anderson, and talked about milestones and hurdles moving forward. Have a listen below: